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A truncating PET100 variant causing fatal infantile
lactic acidosis and isolated cytochrome c oxidase
deficiency
Monika Oláhová1, Tobias B Haack2,3, Charlotte L Alston1, Jessica AC Houghton1, Langping He1,
Andrew AM Morris4, Garry K Brown5, Robert McFarland1, Zofia MA Chrzanowska-Lightowlers1,
Robert N Lightowlers1, Holger Prokisch2,3 and Robert W Taylor*,1
Isolated mitochondrial complex IV (cytochrome c oxidase) deficiency is an important cause of mitochondrial disease in children
and adults. It is genetically heterogeneous, given that both mtDNA-encoded and nuclear-encoded gene products contribute to
structural components and assembly factors. Pathogenic variants within these proteins are associated with clinical variability
ranging from isolated organ involvement to multisystem disease presentations. Defects in more than 10 complex IV assembly
factors have been described including a recent Lebanese founder mutation in PET100 in patients presenting with Leigh
syndrome. We report the clinical and molecular investigation of a patient with a fatal, neonatal-onset isolated complex IV
deficiency associated with multiorgan involvement born to consanguineous, first-cousin British Asian parents. Exome sequencing
revealed a homozygous truncating variant (c.142C4T, p.(Gln48*)) in the PET100 gene that results in a complete loss of
enzyme activity and assembly of the holocomplex. Our report confirms PET100 mutation as an important cause of isolated
complex IV deficiency outside of the Lebanese population, extending the phenotypic spectrum associated with abnormalities
within this gene.
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INTRODUCTION
Mitochondrial oxidative phosphorylation (OXPHOS) is the primary
pathway for adenosine triphosphate (ATP) production in eukaryotic
cells. This OXPHOS system comprises five transmembrane complexes
(I–V) consisting of ~ 90 protein subunits that are encoded by either
the mitochondria’s own genetic material (mtDNA) or the nuclear
genome. Of these, complexes I–IV constitute the respiratory chain and
complex V, the ATP synthase. Mitochondrial respiratory chain disease
is caused by defective OXPHOS and represents a major inborn error
of metabolism.1 Mitochondrial disease is associated with both a varied
age of onset and a diverse spectrum of clinical presentations in which
brain, CNS and muscle involvement are common.2 The hallmark
clinical and genetic heterogeneity of mitochondrial disease is fre-
quently compounded by the lack of clear genotype–phenotype
correlations,3 although biochemical assessment of respiratory chain
complex activities in skeletal muscle is often helpful in guiding
molecular genetic diagnostic testing. For many patients, especially
children, the genetic aetiology of their condition remains unknown.
Complex IV (also known as cytochrome c oxidase (COX)) is the
terminal enzyme complex of the mitochondrial respiratory chain,
catalysing electron transfer from cytochrome c to molecular oxygen,
thus contributing to the proton gradient across the inner mitochon-
drial membrane that drives ATP synthesis.4 The human COX enzyme
comprises 14 structural subunits, 3 of which are of mitochondrial
origin and form the catalytic core.5,6 The remaining components are
translated on cytosolic ribosomes and imported into mitochondria.
The incorporation of all 14 polypeptides to form a mature complex IV
is an intricate process orchestrated by over 20 different assembly
factors.5,7 Recessively inherited defects in several COX assembly
proteins result in the failure to assemble a functional holoenzyme
and underlie a number of mitochondrial respiratory chain disease
presentations characterised by isolated COX deficiency. The clinical
manifestation of COX deficiency includes severe myopathy, cardio-
myopathy, liver failure and Leigh syndrome, a progressive, subacute,
necrotising encephalopathy that is commonly associated with deleter-
ious variants in the SURF1 gene.8,9 SURF1 is an accessory protein
related to the yeast Shy10,11 that facilitates heme a insertion into COX1
in the early steps of complex IV biogenesis.12,13 Although pathogenic
variants in a number of other nuclear-encoded complex IV biogenesis
factors have been identified (COA5,14 TACO1,15 LRPPRC,16
COX10,17 COX15,18 SCO1,19 SCO2,19 and COX2020), the precise
mechanism(s) that control COX assembly remain unclear.
Here, we report the application of whole exome sequencing to
elucidate the basis of an isolated COX deficiency in a pediatric patient
with a severe and fatal neonatal presentation of mitochondrial disease
due to a homozygous truncating variant in the PET100 gene. Previous
studies in yeast identified PET100 gene as a COX biogenesis
factor,21–23 and more recently a Lebanese PET100 founder mutation
has been described in 10 individuals presenting with Leigh
syndrome.24 Fibroblasts and skeletal muscle of our patient showed
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impaired complex IV activity, associated with a profound defect in
COX assembly, and decreased steady-state levels of complex IV
proteins. These data provide further evidence that PET100 is an




Our patient (ID 73387) is a female child, born by an emergency caesarean
section at 34 weeks of gestation to consanguineous, first-cousin British
Pakistani parents. Antenatal scans showed that she was small for her gestation,
weighing 1.19 kg at birth with a head circumference of 26.7 cm, considerably
below the 0.4th centile. Induction of labour had been attempted because of the
growth retardation but had failed, leading to the emergency caesarean section.
The Apgar scores were 4 at 1 min, 7 at 5 min and 9 at 10min. She was admitted
to the neonatal intensive care unit for continuous positive airway pressure
ventilation.
At a few hours of age, she developed a severe lactic acidosis. The initial lactic
acid concentration was 22mmol/l and subsequently increased to 63mmol/l
(normal range, 0.7–2.1mmol/l). She was treated with intravenous infusions of
sodium bicarbonate and Tris-hydroxymethyl aminomethane (THAM), but it
was never possible to correct the metabolic acidosis. She also developed
hypoglycaemia within hours of birth that was corrected with an intravenous
infusion of 15% glucose (7.8mg/kg/min). The ammonia concentration was
normal. Urine organic acid profile showed massive excretion of lactic acid and
increased phenolic acids, especially hydroxyphenyllactate. Plasma amino acids
showed raised concentrations of alanine and glutamine (1567 and 1369 μmol/l,
respectively), consistent with the lactic acidosis; several other amino acids were
also mildly increased. There was gross generalised aminoaciduria. Blood
acylcarnitine analysis was normal. Echocardiography showed a structurally
normal heart and good ventricular function. Cranial ultrasound showed
bilateral intraventricular cysts within the frontal horns and anterior portions
of the lateral ventricles. The left-sided cysts were larger, up to 15mm in
diameter, whereas the largest cyst on the right was 8mm in diameter. The
choroid plexuses were hyperechoic and irregular, suggesting previous intraven-
tricular haemorrhage. Abdominal ultrasound showed a distended urinary
bladder but was otherwise unremarkable. There was severe coagulopathy with
an extended prothrombin time of 47.7 s (normal 12.3–16.6 s), a very low
plasma albumin of 7 g/l (normal 35–50 g/l), otherwise normal liver function
tests but a raised creatine kinase of 2700 U/l (normal o300 U/l).
She was transferred to a tertiary centre because of her worsening metabolic
acidosis. She started having seizures at ∼ 48 h of age. Despite infusions of
bicarbonate and THAM, her acidosis continued to worsen. Muscle and skin
biopsies were performed and the family agreed to the withdrawal of intensive
care treatment. She died aged 55 h. All documented studies were approved and
performed under the ethical guidelines issued by each of our Institutions for
clinical studies, with written informed consent obtained from the family.
Cell culture
Fibroblasts from the affected individual and age-matched controls were
cultured in Eagle’s minimal essential medium (Sigma, Gillingham, UK)
supplemented with 10% (v/v) fetal calf serum, 1× non‐essential amino acids,
1 mM sodium pyruvate and 50 μg/ml uridine, humidified at 37 °C and 5% CO2.
Muscle histology and biochemistry
Informed consents with appropriate ethics review committee approvals were
obtained. Histological and histochemical analyses were performed on 10 μm
transversely orientated serial cryosections of skeletal muscle biopsy samples
using standard procedures. The activities of individual respiratory chain
complex activities and citrate synthase, a mitochondrial matrix marker, were
determined in muscle homogenates and cultured skin fibroblasts as previously
described.25
Molecular genetics
Total genomic DNA was obtained using standard methods and the coding
region plus intron–exon boundaries of several COX assembly (SURF1, SCO1,
SCO2, COX10, COX14, COX15, COA5, LRPPRC, TACO1, FAM37A) and
structural (NDUFA4) genes were amplified using locus-specific primers
(sequences available upon request), sequenced using the BigDye v3.1 kit and
capillary electrophoresed on the ABI3130xl fluorescent sequencing platform
(Life Technologies, Warrington, UK).
Whole exome sequencing was undertaken to investigate the genetic basis of
this child’s mitochondrial disease presentation as previously described.26 A
SureSelect Human All Exon 50Mb V5 Kit (Agilent, Santa Clara, CA, USA) was
used for enrichment of coding DNA fragments and sequencing was performed
on a HiSeq2000 system (Illumina, San Diego, CA, USA). BWA (version 0.5.8)
was used for read alignment to the human reference assembly (hg19) and
single-nucleotide variants (SNVs) and small insertions and deletions were
detected with SAMtools (version 0.1.7). The average coverage was 128-fold and
497% of the target region was covered at least 20-fold allowing for high-
confidence variant calls. Detailed sequencing statistics are provided in Table 1.
Cell lyses and western blotting
Cultured fibroblasts were harvested and lysed in 50mM Tris-HCl pH 7.5,
130mM NaCl, 2mM MgCl2, 1 mM phenylmethanesulfonyl fluoride (PMSF), 1%
Nonidet P-40 (v/v) and 1× EDTA free protease inhibitor cocktail (Pierce,
Rockford, IL, USA). Protein lysates (40 μg) were separated according to size on
12% gels by sodium dodecyl sulphate—polyacrylamide gel electrophoresis
(SDS-PAGE) and electrophoretically transferred to a PVDF membrane
(Immobilon-P, Millipore Corporation, Darmstadt, Germany). Immunoblotting
was performed using primary and HRP-conjugated secondary antibodies.
Mitochondrial preparation and blue native electrophoresis
Cultured fibroblasts were harvested, resuspended in homogenisation buffer
(HB) (0.6 M mannitol, 1 mM ethylene glycol tetraacetic acid, 10mM Tris-HCl
pH 7.4, 1mM PMSF and 0.1% (v/v) bovine serum albumin (BSA)) and
subjected to 3× 15 passes of homogenisation using a Teflon glass Dounce
homogeniser at 4 °C. Standard differential centrifugation (400 g for 10min) was
used to remove nuclei and cell debris and mitochondria were finally pelleted at
11 000 g for 10min at 4 °C. Mitochondria were washed in HB without BSA and
the final pellet was solubilised by n-Dodecyl β-D-maltoside (DDM) (Sigma) at
2mg/mg protein on ice for 20min. Following centrifugation (100 000 g for
15min at 4 °C) the supernatant was collected and Coomassie Blue G-250 (AMS
Biotechnology (Europe) Ltd, Abingdon, UK) was added. Mitochondrial
membrane proteins (50 μg) were loaded on a NativePAGE 4–16% BisTris gel
(Life Technologies), electrophoretically separated and transferred to a PVDF
membrane. The membrane was subsequently immunoblotted with antibodies
raised against OXPHOS complexes.
Immunoblotting
The following primary antibodies were used for immunoblotting: NDUFA9
(Molecular Probes, Eugene, OR, USA, A21344), NDUFB8 (Abcam, Cambridge,
UK, ab110242), SDHA (MitoSciences, Eugene, OR, USA, MS204), UQCRC2
(Abcam, ab14745), COX1 (Abcam, ab14705) and COX2 (Molecular Probes,
A6404), ATP5A (Abcam, ab14748), ATPB (Abcam, ab14730) and TOM20
Table 1 Variants identified at different filtering levels in individual no.
73387
Variants filtering
Synonymous variants 11 836
Nonsynonymous variants (NSVs) 12 576
NSVs absent from 3600 control exomes and public databases 313
Genes carrying ≥2 NSVs 38
Genes carrying ≥2 loss-of-function alleles 1 (PET100)
NSVs indicate missense, nonsense, stop/loss, splice site disruption, insertions and deletions.
The bold entry indicates the affected gene (PET100).
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(Santa Cruz, Heidelberg, Germany, sc11415). HRP-conjugated anti-mouse or
anti-rabbit secondary antibodies were used (P0260 and P0399 respectively;
Dako, Glostrup, Denmark). Chemiluminescence ECL Prime Kit (Amersham,
Little Chalfont, UK) and ChemiDocMP Imaging System (Bio-Rad, Hemel
Hempstead, UK) were used for signal detection and Image lab 4.0.1 (Bio-Rad)
software for analysis.
RESULTS
Muscle histochemistry and respiratory chain analyses
Analysis of the patient’s muscle biopsy demonstrated a severe and
global loss of COX histochemical activity throughout the section (not
shown), confirmed by the spectrophotometric assay of respiratory
chain activities, that demonstrated a severe and isolated deficiency of
complex IV in muscle homogenates (Figure 1a). This observation was
confirmed in patient fibroblasts in which complex IV activity was
markedly decreased (Figure 1b).
Molecular genetic studies identify a novel truncating PET100
variant
Sanger sequencing of several COX assembly genes and structural
components did not identify causative variants, prompting whole
exome sequencing. Prioritisation of candidate disease genes was
performed essentially as reported previously,27 with our analysis
focussing on nonsynonymous variants. Based on the rare disease
phenotype we expected disease-causal variants to have a low frequency
in the general population, and hence we excluded detected variants
present in 3600 control exomes and public databases. Assuming an
autosomal recessive mode of inheritance, we searched for genes
carrying predicted compound heterozygous or homozygous variants
(Table 1). This filter left 38 genes. Two genes, namely MYH14
(MIM*608568) and ANKS6 (MIM*615370), have been previously
linked to human disease. Variants in both were excluded as likely
candidates because of different clinical presentations, reportedly
autosomal dominant mode of inheritance in the case of MYH14,
and the fact that both heterozygous ANKS6 variants were confirmed
to be in cis on the same allele. Only one gene, PET100
(NM_001171155.1), carried two predicted loss-of-function alleles.
The patient was homozygous, for a truncating PET100 variant
(c.[142C4T];[142C4T], p.[(Gln48*)];[(Gln48*)]; ClinVar Reference
ID: mdi-3317) that resides in the fourth coding exon and predicts a
truncated protein in which the last 26 amino acids are lost (33% of the
full-length protein). Concordant with a disease-causal role of the
homozygous (c.142C4T, p.(Gln48*)) variant, confirmatory Sanger
sequencing revealed that both healthy parents were heterozygous
carriers (Figure 1c).
Mutation of PET100 leads to impaired complex IV assembly
Further characterisation of the nature of the biochemical defect
associated with the PET100 variant was performed in patient
fibroblasts. The steady-state levels of individual OXPHOS complex
subunits and the subsequent assembly into mitochondrial respiratory
chain complexes were analyzed by Blue-native PAGE (BN-PAGE) and
SDS-PAGE respectively.
The analysis of the steady-state levels of OXPHOS complex
components confirmed a marked decrease in COXI and COXII in
patient compared with control fibroblasts (Figure 2a). No significant
changes were detected in any of the steady-state levels of all other
analyzed complexes (I, II, III and V), although in agreement with the
respiratory chain enzyme results in muscle, there was a suggestion that
complex III levels were increased ~ 1.6-fold based on densitometric
analysis (Figure 2a). A similar observation has been made previously in
patients harbouring pathogenic variants in another COX assembly
gene, SURF1.28 TOM20 was used as a mitochondrial loading marker
and confirmed equal loading of control and patient mitochondrial
protein.
Consistent with this reduction in steady-state levels of CIV proteins
and the biochemical measurements of the respiratory chain complex
activities (Figure 1b), BN-PAGE analysis revealed significantly
decreased amounts of fully assembled complex IV in patient cells
compared with age-matched controls (Figure 2b). This loss of
OXPHOS complex was specific as the assembly profile of complexes
I, II, III and V were normal.
These data demonstrate that the consequence of the homozygous p.
(Gln48*) PET100 variant is a specific and severe loss of COX subunits
and fully assembled complex IV.
DISCUSSION
Although recognised as one of the most common energy metabolism
disorders, isolated COX deficiency has a diverse genetic aetiology that
reflects the complex nature of biogenesis and assembly of mtDNA-
and nuclear-encoded components into mature holoenzyme; a process
facilitated by numerous chaperone proteins. Pathogenic variants in a
number of the assembly factors necessary for the formation of a
functional COX enzyme have been reported.9,14–20 Recently, a founder
mutation in a highly conserved COX assembly factor PET100 has been
identified in 10 Lebanese individuals with isolated COX deficiency
who present with Leigh syndrome and seizures.24
Here we report that a new truncating PET100 variant causes fatal
infantile lactic acidosis and isolated COX deficiency in a child born to
consanguineous British Pakistani parents. The pathogenic nonsense
(c.142C4T, p.(Gln48*)) variant in the PET100 gene was identified by
whole exome sequencing, leading to impaired complex IV enzyme
Figure 1 Identification of an isolated mitochondrial respiratory chain
complex IV deficiency in muscle and fibroblasts and analysis of PET100
variant. The assessment of individual respiratory chain enzyme activities in
muscle (a) and fibroblasts (b) identified a severe OXPHOS deficiency
affecting complex IV in isolation in the patient (blue bars) compared with
controls (red bars); mean enzyme activities shown for muscle controls
(n=25) and fibroblast controls (n=10) are set at 100%. (c) Family
pedigree showing confirmation of p.(Gln48*) carrier status in clinically
unaffected parents, whereas the proband is homozygous for the truncating
variant.
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activity and abnormal COX assembly. Our results are consistent with
previously published data suggesting that PET100 is a conserved
biogenesis factor involved in the maturation of complex IV in both
humans24 and yeast.21–23 The yeast homologue of PET100 is not
necessary for the localisation of COX polypeptides to the inner
mitochondrial membrane,21 but it has a major role in the later
assembly processes where it facilitates the assembly of COX
intermediates.23 In contrast, human PET100 appears to be required
earlier in the process for the assembly of mitochondrial-encoded COX
subunits.24 Our results demonstrate the importance of PET100 in
OXPHOS function and support previous studies;21–24 however, it
requires further investigation to fully understand the exact role of this
enzyme in the maturation of the COX holoenzyme.
The complex IV assembly profile observed in our patient with this
truncating PET100 variant is similar to the reported Lebanese
(c.3G4C, p.?) PET100 variant that eliminates the initiation codon
potentially resulting in a nonfunctional protein.24 However, our study
has identified some key differences in the biochemical and clinical
disease presentations between the two variants. The residual complex
IV enzyme activities were lower in our patient’s fibroblasts and skeletal
muscle compared with the residual COX activities demonstrated in
tissues from the Lebanese patients. The COX defect in the patients
carrying the Lebanese (c.3G4C, p.?) variant was associated with Leigh
syndrome, seizures, developmental delay and elevated blood lactate levels,
although these were variable (ranging from normal to 11mmol/l).24
These symptoms were apparent a few months after birth. In contrast,
the onset of the disease in our patient was before birth and her lactate
levels were extremely high (63mmol/l at its peak). Further differences
in our patient’s clinical presentation were marked hypoglycaemia,
severely impaired liver function and raised creatine kinase reflecting
profound disruption of metabolic energy homeostasis. These observa-
tions in our patient suggest that impairment of PET100 can lead to
severe complications, including prenatal onset and neonatal death, not
observed in the other reported PET100 variant. Interestingly, Lebanese
individuals harbouring the PET100 truncating variant differ from
patients with mutations in SURF1, a different COX assembly factor, in
that seizures appear to have an earlier age of onset.24,29 Consistent
with this, our microcephalic patient showed abnormalities on neuroi-
maging and suffered seizures from 48 h of age that are likely to reflect
severe problems with in utero brain development. The truncating
nature of the PET100 variant may cause the protein to be subject to
nonsense-mediated mRNA decay or may otherwise exert a dominant
negative effect that in turn determines the severity and early
appearance of clinical disease. Importantly, although a PET100 variant
has only been identified in patients originating from Lebanon to date,
our patient shows that mutations within this gene occur outside of this
particular ethnic group.
Whole exome sequencing is a rapid and effective approach to
elucidate the molecular bases of mitochondrial respiratory chain
disorders including isolated COX deficiency.30,31 Our findings confirm
PET100 as an important candidate disease gene in patients with isolated
COX deficiency. Recent advances in next-generation sequencing enable
the rapid and accurate diagnosis of singleton mitochondrial disease
patients within small families, thus facilitating appropriate counselling
and the offer of preventive strategies, such as prenatal diagnosis and
preimplantation genetic profiling.
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